Corporate Banner
Satellite Banner
Pharma Outsourcing
Scientific Community
 
Become a Member | Sign in
Home>Events>This Event
  Events - March 2013


18th Congress of The European Association of Hospital Pharmacists (EAHP)

13 Mar 2013 - 15 Mar 2013 - Palais des Congrès, Paris, France



Bookmark and Share


The European Association of Hospital Pharmacists (EAHP) is a working community of national associations of hospital pharmacists. Membership is increasing each year and, at present, EAHP represents the interest of over 21,000 hospital pharmacists in 32 countries all over Europe.

EAHP’s annual congress is the largest congress for hospital pharmacy in Europe and is attended by professionals from over 50 countries. Approximately 4.000 hospital pharmacists are expected to attend the 18th Congress of the EAHP next 13-15 March 2013 at the Palais des Congrès in Paris, France.

“Improving patient outcomes – a shared responsibility”  will be the theme for the presentations at the Paris 2013 EAHP Congress. A scientific programme including 3 keynote presentations, 13 seminars open for interactions with the speakers and 3 interactive workshops will offer participants the unique opportunity to meet, network and share expertise. EAHP’s industry partners have also committed to conducting satellite symposia highlighting important new developments important to hospital pharmacy.

EAHP’s Congress is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education, as well as by some of its national member associations according to the different national accreditation systems.

REGISTRATION OPEN 1 AUGUST 2012:
Register online to attend the EAHP 18th Congress.

CALL FOR ABSTRACTS: 
Deadline for submission is 15 October 2012.  Original contributions from all fields of hospital pharmacy are welcomed for poster presentation. 

For further information, please visit the website, where you will also be able to find more details on our scientific programme.

The registration fees are set follows :

 

— before 1 December 2012  € 600

— beginning 1 December 2012 € 700

— beginning 1 February 2013 € 800

 

Registration fee includes access to all sessions, the opening reception, the exhibition, lunches on Wednesday, Thursday, Friday and coffee/tea during official breaks.

 

Registration fee includes 19,6% VAT until 1 October and 21,2% afterwards according to French law.



Further information
Scientific News
NIH Begins Yellow Fever Vaccine Trial
NIH has initiated an early-stage clinical trial of a vaccine to protect against yellow fever.
Viable HIV Vaccine Confirmed by Study
HIV Study in macaques confirms clinically viable vaccine opening the way for future treatment in humans.
PREVAIL Treatment Trial for Men with Persistent Ebola Viral RNA
The six-month study will enroll 60 to 120 EVD survivors.
What Makes a Good Scientist?
It’s the journey, not just the destination that counts as a scientist when conducting research.
Investigational Malaria Vaccine Protects Healthy U.S. Adults
Researchers at NIH have found that the malaria vaccine protected a small number of healthy, malaria-naïve adults in the U.S. from infection for more than one year after immunization.
AACR 2016: Cancer Immunotherapy and Beyond
At this year's meeting there was a palpable buzz around subjects ranging from microbiomics to the tumor microenvironment and cancer vaccines, big data to in vitro and in vivo modeling and drug delivery (to name just a few).
New Database for Sharing MS Clinical Trial Data
A new database containing nearly 2500 patient records from the placebo arms of nine multiple sclerosis (MS) clinical trials is now available for research by qualified investigators.
Study Finds Factors That May Influence Influenza Vaccine Effectiveness
Researchers at NIH have suggested that the long-held approach to predicting seasonal influenza vaccine effectiveness may need to be revisited.
BMS’s Opdivo Clinical Trial Shows Promise
Safety profile of the combination regimen from CheckMate -069 was consistent with previously reported studies and adverse events were managed using established safety algorithms.
Treatment of Common Prostate Cancer
Researchers at UTSW have found that the prostate cancer treatments suppress immune response and may promote relapse.
Scroll Up
Scroll Down
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,300+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,900+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!